CSOP NASDAQ-100 Index Daily (-2x) Inverse Product (07568.HK) Rises 2.46% in Morning Trade, Turnover at HKD 3.6871 Million
NewTimeSpace News: As of 9:42 on June 17, 2026, CSOP NASDAQ-100 Index Daily (-2x) Inverse Product (07568.HK) edged up 2.46%, trading at HKD 2.250. The ETF opened today at HKD 2.256, with 1.6384 million shares traded, a turnover of HKD 3.6871 million, and an average price of HKD 2.250. The Net Asset Value (NAV) stood at HKD 2.267, with total Assets Under Management (AUM) of HKD 1.425 billion.
CSOP NASDAQ-100 Index Daily (-2x) Inverse Product (07568.HK) tracks the Nasdaq 100 Index, which comprises the top 100 largest non-financial companies listed on Nasdaq by market capitalization. Its constituents are heavily concentrated in high-growth sectors including technology, communication services and consumer discretionary.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ALPHAMAB-B(09966.HK): CDE Grants Approval for Phase III Clinical Trial of JSKN033 in Cervical Cancer
- Touyun Biotech (01332.HK): Appointment of Zhou Ruijuan as Executive Director and Vice Chairman
- Innogen-B (02591.HK): Two Contract Manufacturing Sites for Isupaglutide α Injection Obtain PIC/S GMP Certificates
- CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China
- Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies